Introduction: RenaissThera, a Bengaluru-based startup, is working on designing oral drugs for obesity and type 2 diabetes, focusing on cardio-metabolic disease. Founded in 2023 by Dr Ramkesh Meena and Sudhir Nagarajan, the company aims to develop affordable therapies for patients in markets that newer drugs reach late or not at all. RenaissThera has already made significant progress, with seven small-molecule programmes at the discovery stage, all targeting GLP-1 and GIP receptors.
The company's approach is to find small molecules that act on receptors already proven to work, rather than searching for a completely new biological mechanism. This reduces the risk associated with drug discovery, as the target is already proven to matter. RenaissThera's focus is on designing a molecule small enough to be taken as a pill, which would be cheaper to make and easier to distribute than existing peptide-based treatments.
RenaissThera's pipeline includes seven small-molecule programmes, with two targeting GLP-1 and GIP separately, one blocking GIP, two combining both receptors, and two targeting apelin, a separate metabolic target. All seven programmes are at the discovery stage, and the company is using AI and machine learning tools to design and screen molecules.
What Happened
RenaissThera was founded in 2023 with the goal of developing affordable therapies for patients in markets that newer drugs reach late or not at all. The company has already made significant progress, with seven small-molecule programmes at the discovery stage. In October 2024, RenaissThera entered a drug discovery collaboration with VedTechBio, a Bengaluru firm whose platform it uses alongside dedicated research teams.
In June 2025, the company announced a discovery milestone in its oral obesity programme, with molecules targeting the GIP receptor showing activity in cell lines and animal studies. Although this is a significant achievement, it is essential to note that these results have not gone through peer review or been tested on people.
RenaissThera has also received funding to support its research and development efforts. The company closed a first seed round backed by angel investors in December 2024 and joined the incubation programme at C-CAMP, the Bengaluru research and innovation centre, in November 2025. In June 2026, RenaissThera announced a further seed round led by Arali Ventures, an enterprise technology fund investing from a $35 million second fund.
Background
RenaissThera's focus on cardio-metabolic disease is driven by the growing need for effective treatments for obesity and type 2 diabetes. According to the World Health Organization, obesity has tripled since 1975, and type 2 diabetes is a major cause of premature death and disability. Existing treatments for these conditions often have limitations, such as the need for injection or cold storage, which can make them expensive and inaccessible to many patients.
Timeline
2023: RenaissThera was founded by Dr Ramkesh Meena and Sudhir Nagarajan.
2024: The company closed a first seed round backed by angel investors in December.
2024: RenaissThera entered a drug discovery collaboration with VedTechBio in October.
2025: The company joined the incubation programme at C-CAMP in November and presented at BioAsia in Hyderabad in February.
2025: RenaissThera announced a discovery milestone in its oral obesity programme in June.
2026: The company announced a further seed round led by Arali Ventures in June.
Why It Matters
RenaissThera's work on designing oral drugs for obesity and type 2 diabetes has the potential to make a significant impact on public health. If successful, these treatments could provide a more accessible and affordable option for patients, particularly in markets where existing treatments are not readily available. The company's focus on cardio-metabolic disease also highlights the need for continued innovation in this area, as the prevalence of obesity and type 2 diabetes continues to grow.
The use of AI and machine learning tools in RenaissThera's research and development efforts also demonstrates the potential for technology to accelerate the discovery of new treatments. By leveraging these tools, the company can design and screen molecules more efficiently, reducing the time and cost associated with traditional drug discovery methods.
Industry Impact
RenaissThera's work on oral drugs for obesity and type 2 diabetes is part of a broader trend in the pharmaceutical industry towards the development of more accessible and affordable treatments. The company's focus on cardio-metabolic disease also highlights the need for continued innovation in this area, as the prevalence of obesity and type 2 diabetes continues to grow.
Analysis
RenaissThera's approach to drug discovery, using AI and machine learning tools to design and screen molecules, has the potential to disrupt traditional methods of drug development. The company's focus on cardio-metabolic disease also demonstrates the need for continued innovation in this area, as the prevalence of obesity and type 2 diabetes continues to grow.
Key Takeaways
RenaissThera is developing oral drugs for obesity and type 2 diabetes, focusing on cardio-metabolic disease.
The company has seven small-molecule programmes at the discovery stage, all targeting GLP-1 and GIP receptors.
RenaissThera is using AI and machine learning tools to design and screen molecules.
The company has received funding to support its research and development efforts, including a seed round led by Arali Ventures.
RenaissThera's work has the potential to make a significant impact on public health, particularly in markets where existing treatments are not readily available.
The company's approach to drug discovery has the potential to disrupt traditional methods of drug development.
Conclusion
RenaissThera's work on designing oral drugs for obesity and type 2 diabetes is a significant development in the pharmaceutical industry. The company's focus on cardio-metabolic disease and its use of AI and machine learning tools demonstrate the potential for innovation to drive the discovery of new treatments. As RenaissThera continues to progress its research and development efforts, it will be important to watch for further updates on the company's progress and the potential impact of its work on public health.
The next major milestone for RenaissThera will be the submission of an Investigational New Drug (IND) application, which will mark a significant step towards the potential approval of its oral drugs for obesity and type 2 diabetes. With its strong pipeline and innovative approach to drug discovery, RenaissThera is well-positioned to make a significant impact in the pharmaceutical industry and improve the lives of patients around the world.
